Dr. Forrest was most recently Chief Strategy Officer of Cidara Therapeutics (Nasdaq: CDTX) an infectious disease company he co-founded in 2013 and helped take public as COO/CFO in 2015. At Cidara he was responsible for the acquisition of rezafungin, a preclinical stage novel long acting echinocandin antifungal currently in late stage clinical studies. He is also a co-inventor of the company’s Cloudbreak™ antimicrobial immunotherapy platform. From 2005 to 2014, Dr. Forrest held positions of increasing responsibility at 5AM Ventures, an early stage life science venture capital firm. While at 5AM, Dr. Forrest supported the spin-out of Relypsa (acquired by Galenica) from Ilypsa/Amgen and led or supported investments in Semprus Biosciences (acquired by Teleflex), Marcadia Biotechnologies (acquired by Roche), Flexion Therapeutics (Nasdaq: FLXN), among others. Dr. Forrest serves as a review member of the Princeton University IP Accelerator Fund, and co-leads organization of the rEvolution Symposium, a leading meeting for heads of life science R&D. Dr. Forrest holds a B.S. in biology from Boston College and Ph.D. in molecular biology from Princeton University where he developed novel in vivo imaging tools to examine RNA localization and translational control.